Firstly, in lymphomas treated with rituximab, both genotypes have independently been associated with higher response rates and longer progression‐free survival (PFS) in follicular lymphoma (FL) (Weng and Levy 2003) and the FCGR3A‐158V variant has been associated with favorable clinical response rates in FL,241, 242 mantle cell lymphoma (MCL),243 diffuse large B‐cell lymphoma (DLBCL),244, 245 and non‐Hodgkin lymphoma (NHL) in general.246. Here, FCGR3A is linked to mantle cell lymphoma.